Home    Back

Caveolin-1-scaffolding-protein-derived peptide (lti-03)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia1

85. Idiopathic interstitial pneumonia    [ 514 clinical trials,   377 drugs,   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways]
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04233814
(ClinicalTrials.gov)		January 20, 202012/1/2020Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult SubjectsA Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose & Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult SubjectsIdiopathic Pulmonary FibrosisDrug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03);Drug: PlaceboLung Therapeutics, IncNULLSuspended18 Years55 YearsAll56Phase 1United Kingdom